RxDoctor Payments Data

Candacy George, DO

Family Medicine · Carneys Point, NJNPI 1841690021

Payments from drug & device makers

$344in general payments, 2019–2025

Across 15 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$125
  • Novo Nordisk$68
  • AbbVie$67
  • Lilly USA, LLC$30
  • Novartis$21
  • Alkermes, Inc.$20
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$344100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen1$125
Novo Nordisk5$68
AbbVie4$67
Lilly USA, LLC2$30
Novartis1$21
Alkermes, Inc.1$20
Abbott1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$344 in reported general payments places this provider in the 45th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$81,744
Medicare patients
322
Services billed
1,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$100,634
MounjaroTirzepatide55$82,748
JardianceEmpagliflozin40$62,737
TrulicityDulaglutide23$56,250
EliquisApixaban41$53,071
XareltoRivaroxaban39$33,680
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$30,995
InvokanaCanagliflozin18$29,567
Bydureon BciseExenatide Microspheres21$25,055
FarxigaDapagliflozin Propanediol18$13,882
Arnuity ElliptaFluticasone Furoate16$7,046
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$6,844
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$6,355
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,787
Albuterol Sulfate HfaAlbuterol Sulfate86$4,693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$30$138,99878 claims
Novo NordiskOzempic$68$100,63477 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Carneys Point

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →